Seeking Alpha
11 Oct 2025, 12:13 UTC · 48w ago
Verdict
Headline takes no side. We score NRIX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Nurix Therapeutics plans to initiate a pivotal single-arm phase 2 study for bexobrutideg in 2H 2025, potentially enabling Accelerated Approval.
More positive than 99% of claims this week
Bexobrutideg demonstrated an 80.9% overall response rate (ORR) in phase 1a data for relapsed/refractory CLL.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 96% of claims this week
Future development includes a phase 3 randomized trial and combination therapies targeting 1st- and 2nd-line CLL, addressing a multibillion-dollar market opportunity.
More positive than 91% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Maintains a Strong Buy rating due to promising progress and market opportunity for bexobrutideg.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1d ago
+160.4%
Price agrees with the score
$25.41 vs $9.76 close before publication (Oct 10) · not market-adjusted
NRIX chart →
